---
title: The ENCHANTMENT HIV Study
nct_id: NCT04153136
overall_status: COMPLETED
phase: PHASE2
sponsor: Massachusetts General Hospital
study_type: INTERVENTIONAL
primary_condition: HIV/AIDS
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04153136.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04153136"
ct_last_update_post_date: 2026-03-11
last_seen_at: "2026-05-12T07:21:11.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The ENCHANTMENT HIV Study

**Official Title:** Ending Subclinical Heart Failure Using an Aldosterone and Natriuretic Peptide Targeted Treatment in HIV--The ENCHANTMENT HIV Study

**NCT ID:** [NCT04153136](https://clinicaltrials.gov/study/NCT04153136)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 39
- **Lead Sponsor:** Massachusetts General Hospital
- **Conditions:** HIV/AIDS, Heart Failure With Preserved Ejection Fraction
- **Start Date:** 2020-09-11
- **Completion Date:** 2025-07-09
- **CT.gov Last Update:** 2026-03-11

## Brief Summary

Persons with HIV, even those well-treated, are at increased risk for heart disease when compared to the general population. Two hormones called aldosterone and brain natriuretic peptide (BNP), which have been shown to be abnormal in HIV, may be associated with inflammation as well as early changes in structure and function of the heart. This study is being conducted to evaluate whether therapies to block aldosterone and increase BNP levels may reduce the burden and progression of heart failure to improve cardiovascular health.

## Detailed Description

This is a 6-month study enrolling persons with HIV with no known history of heart disease. Participants will be screened for early signs of heart failure using cardiac ultrasound (cardiac transthoracic echocardiography or cardiac TTE). Those participants who have early changes in the structure and function of the heart and may be at future risk for heart failure will be enrolled into the study. Additional imaging of the heart will occur using cardiac magnetic resonance imaging (cardiac MRI). Following baseline studies, participants will either receive a medication called sacubitril/valsartan or placebo for 6 months. Sacubitril/valsartan in an FDA approved medication currently being used for heart failure with reduced ejection fraction in the general population, and we are evaluating whether this medication could be useful to reduce HIV-related heart failure with preserved ejection fraction. Sacubitril/valsartan is an oral medication taken twice daily that may block aldosterone hormone and increase natriuretic peptide hormone. Overall, this study aims to investigate the effect of sacubitril/valsartan on measures of heart disease related to inflammation, structure and function of the heart muscle in HIV using cardiac TTE and cardiac MRI imaging as well as blood markers of heart failure and inflammation.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Antiretroviral therapy use for \>12 months
2. HIV Viral Load \<200 copies/mL
3. Left Ventricular Ejection Fraction\>50%
4. Demonstration of one or more criteria for myocardial dysfunction on cardiac transthoracic echocardiogram, relevant to the progression of heart failure with preserved ejection fraction:

   * Left Atrial Volume Index \> 28 mL/m2
   * Global Longitudinal Strain \<18%
   * Left Ventricular Mass Index \> 95g/m2 (female), 115 g/m2 (male)

Exclusion Criteria:

1. Known history of congestive heart failure or valvular disease
2. Recent cardiac event or stroke within 3 months
3. Current medication use acting along the RAAS pathway (ACEi, ARB, MR blockade, direct renin inhibitor), potassium (K) supplementation or diuretic
4. Angioedema to ACEi or ARB
5. SBP\<100 mmHg
6. Medication suspected to have contraindication with active study drug
7. Steroid use within last 3 months
8. Uncontrolled diabetes requiring insulin and/or HbA1c \> 7.5%
9. Creatinine (Cr)\>1.5 mg/dL and estimated GFR\<60 mL/min/1.73m2
10. K\>5.5 mEq/L
11. Hemoglobin \<10.0 g/dL
12. Known liver disease or ALT\>3x upper limit normal
13. Pregnant, actively seeking pregnancy or breastfeeding
14. Estrogen, progestin derivative, or other sex steroid use within 3 months. Stable physiologic testosterone replacement (\> 3 months) is acceptable
15. Current bacterial or other infection
16. Active substance abuse
17. Known reaction to gadolinium
```

## Arms

- **Sacubitril/Valsartan** (EXPERIMENTAL) — Sacubitril/Valsartan 49-51mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 6 months
- **Placebo** (PLACEBO_COMPARATOR) — Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 6 months

## Interventions

- **Sacubitril-Valsartan 49-51Mg Oral Tablet** (DRUG) — By mouth twice daily
- **Placebo oral tablet** (DRUG) — Placebo oral tablet By mouth twice daily

## Primary Outcomes

- **Myocardial Inflammation/Fibrosis** _(time frame: 6 months)_ — Myocardial Inflammation/Fibrosis measured by extracellular volume fraction via cardiac magnetic resonance imaging
- **Myocardial Dysfunction** _(time frame: 6 months)_ — Left Atrial Volume Index or Global Longitudinal Strain measured by cardiac transthoracic echocardiography

## Secondary Outcomes

- **Other Indices of Myocardial Dysfunction** _(time frame: 6 months)_
- **Markers of Myocardial Inflammation and Fibrosis** _(time frame: 6 months)_
- **Cardiac Natriuretic Peptides** _(time frame: 6 months)_

## Locations (1)

- Massachusetts General Hospital, Boston, Massachusetts, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.massachusetts general hospital|boston|massachusetts|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04153136.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04153136*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*